A Phase 1 Study of the Safety and Tolerability of CTX-10726

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

Trial Details

NCT ID
NCT07419841
Phase
PHASE1
Sponsor
Compass Therapeutics
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • CTX-10726
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • Lake Success, New York, United States|40.77066,-73.71763

Key Eligibility Criteria

  • Age 18 years or older.
  • Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/re…
  • 2a: Renal Cell Carcinoma (RCC)
  • Histologically confirmed diagnosis of renal cell carcinoma (with clear cell component) with advanced or metastatic disease that is not amenable to …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →